EU approves Merck/Cardiome's Brinavess for atrial fibrillation cardioversion
This article was originally published in Scrip
Executive Summary
The EMA has approved Merck/Cardiome's Brinavess (vernakalant) for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults. The move comes only two months after Brinavess was given the nod by the CHMP (scripintelligence.com, 29 June 2010).